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Abstract
Background and Aims
The substantial characteristics of Irritable Bowel Syndrome (IBS) are associated with estro-
gens in women. Both soy isoflavones and vitamin D can modulate estrogen receptors in the
colonic smooth muscles. The aim of this study was to investigate the effects of soy isofla-
vones, vitamin D and their probable interactions in women with IBS.
Methods
In a factorial blinded randomized clinical trial, 100 women with IBS (age:18-75yr, were ran-
domly assigned in 4 arms to receive either placebo of vitamin D and placebo of soy isofla-
vones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo
of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. Dosage of
soy isoflavone was 2 capsules of 20 mg soy isoflavones per day, and dosage of vitamin D
was one pearl of 50’000 IU biweekly. The clinical outcomes were IBS symptoms severity
scores (IBS-SSS), disease- specific quality of life (IBS-QOL) and total score (IBS-TS) that
evaluated at weeks 0, 6, and 10, and compared to each other.
Results
IBS-TS improved significantly in both S+P and D+P groups (p- value = 0.004, 0.015). The
interaction effect of soy isoflavones and vitamin D on IBS-TS was significant (p<0.05). The
interaction effect of soy isoflavones with vitamin D and the main effect of vitamin D on IBS-
SSS were not statistically significant, whereas IBS-SSS decreased significantly in S+P and
D+P groups (p-value = 0.001, 0.047 respectively).
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Conclusion
Our results indicate that co-administration of soy isoflavones with vitamin D did not improve
the IBS- SSS and IBS- QOL; however, it improved the IBS-TS.
Trial Registration
Clinical Trials.gov NCT02026518
Introduction
Irritable bowel syndrome (IBS) is the most common gastrointestinal problem, which affects 7%
to 21% of the general population [1]. Although the prevalence of this syndrome is high, there is
no proven treatment for it, and current treatments can negatively impact quality of life [2–4].
The probable mechanisms of IBS include alteration of intestinal permeability, visceral motility
and hypersensitivity that can be triggered after an emotional stress [5]. There is a mutual rela-
tionship between psychological and somatic risk factors that induce the lifelong symptoms of
functional bowel disorders [6]. Hectic lifestyle contributes to high risk of IBS after infections
[7] and anxious people experience more frequent and worse symptoms of IBS [8], so that anxi-
ety, stress and emotional illness are associated with increased intestinal permeability and
hypersensitivity [5].
Chronic visceral pain is one of the substantial characteristics of IBS that is associated with
estrogens activity in women [9]. Women with IBS report more frequent functional bowel dis-
orders during their menstrual period [10]. Reduction of estrogens can affect hypersensitivity
and gut permeability of women with IBS [11] that has been shown in experimental Rat model
of IBS [12]. Higher severity of symptoms in IBS is correlated with more gut permeability [13].
In the other hand, estrogen receptors type β (ERβ) are expressed predominantly in colon and
can be activated by estrogen like compounds such as isoflavones and reduce the gut hypersensi-
tivity [12]. Diadzein, glycetin and genistein are soy isoflavones acting as 17- β estradiol with
high affinity to ERβ [14]. Similarly, 1,25 di-hydroxy vitamin D can act as a modulator of ERs
and activate the nuclear signaling of these ERs in the colonic smooth muscles[15]. Up to our
knowledge, there is no clinical study to evaluate the effect of co-administration of isoflavones
and vitamin D on clinical outcomes in IBS. These findings plus a recent report of improvement
of IBS symptoms by high-dose supplementation of vitamin D[15] encouraged us to design a
randomized clinical trial to evaluate the effects of soy isoflavones and vitamin D supplementa-
tion in the management of IBS.
The aim of this study was to investigate the effects of soy isoflavones, vitamin D and their
co-administration effects on symptoms severity scores, disease- specific quality of life and total
score in women with IBS using a factorial randomized clinical trial design.
Materials and Methods
Study design
Women with IBS with age range of 18 to 75 year old and body mass index (BMI) of 18–25
were recruited from the Endoscopy clinic, Shariati Hospital, Tehran, Iran. The ROME III crite-
ria was used for diagnosis of IBS [16]. Inclusion criteria were absence of intestinal organic dis-
eases, intestinal infection, history of colorectal disorders, major intestinal surgery, current use
of antibiotics, anti-diarrhea and anti-constipation drugs, non-steroidal anti-inflammatory
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drugs, metocloperamide, cisaperide, difenoxilate, opium and immune suppressors. The exclu-
sion criteria were use of any type of soy products and/or vitamin D, use of synthetic sweeteners
(due to change of intestinal permeability) 2 days before and during the study. Moreover, preg-
nant and lactating women were not recruited in the study. In addition, patients with history of
breast cancer in herself or her mother and sisters were excluded from the study according to
their self-reporting. Furthermore, diet therapy, hormone therapy and substantial changes in
dietary intakes especially consumption of soy or vitamin D rich foods or supplements during
the study, and no desire to continue participation in the study were considered as exclusion
criteria.
All patients with eligibility criteria started the study in 2013. The study protocol was
approved by Ethics committee of National Nutrition and food Technology Research Institute
(NNFTRI) with registeration number of 92-10-10-459. Before starting the intervention, all par-
ticipants were explained about the intervention, their rights and objectives of the study and
they have signed the written informed consent after acceptance to participate in the study. The
participants were randomly assigned to receive either placebo of vitamin D and placebo of soy
isoflavones (P+P), or placebo of vitamin D and soy isoflavones (P+S), or vitamin D and placebo
of soy isoflavones (D+P), or vitamin D and soy isoflavones (D+S) for 6 weeks. We produced 25
equaled size blocks (size = 4) for allocation of patients to 4 different intervention groups. Ran-
domization was not exposed to those conducting the study and was provided in sealed opaque
envelopes with successive numbers.
The soy isoflavones capsules (21 century co., USA) contained 10 mg of diadzein, 8.5 mg of
genstein and 1.5 mg of glycetin that was taken twice a day. The vitamin D pearls (Zahravi co.,
Iran) consisted of 50000 IU cholecalciferol that was taken one pearl biweekly. The placebos
were in the same shape and color of each homonymous supplement. The placebo of soy isofla-
vones contained 10 mg corn starch and the placebo of vitamin D contained 10 mg medium
chain triglyceride (MCT) oil, and provided by Zahravi Co., Tabriz, Iran. The MCT oil con-
tained 59.4% Caprylic acid, 39.6% Capric acid, 0.7% Caproic acid, 0.2% Lauric acid, and 0.1%
Myristic acid.
Clinical, paraclinical, and dietary intake assessments
The baseline data about personal information, anthropometric data (including weight, height,
BMI, waist circumference (WC)) and dietary recalls for 3 days (2 working days and one holi-
day) was gathered. The dietary recalls were filled by face to face interview and their nutrients
content were calculated using dietary calculator software, Nutritionist IV (First data bank).
NNFTRI validated list of portion sizes of Iranian cuisine and nutritional composition tables
were applied to get accurate data of dietary intake [17].The consumption of soy (foods, supple-
ments) and vitamin D (sun exposure, foods and supplements) was assessed. All participants
were asked to fill in a
validated IBS symptoms severity score (IBS-SSS) questionnaire [18] and, a validated IBS
quality of life (IBS-QOL) questionnaire [19] at week 0 and week 6. IBS-SSS questionnaire con-
sists of 5 items about the severity of abdominal discomfort, frequency of discomfort, severity of
flatulence, satisfaction after defecation and interactive impact of IBS symptoms with everyday
life. Data were collected by face to face interview using visual analog scale (VAS) sum of scales
were transformed to a 500 scale ranging from 0 to 500. IBS- QOL questionnaire has 34 items
including dysphoria (8 items), body image (4 items), health-oriented worries (3 items), sexual
related worries (2 items), social behavior (4 items), intervene with every-day activity (7 items)
and personal relationship (3 items) [20]. This questionnaire based on 5-choice scale (0–4) and
the summed total score was transformed to a 100 scale ranging from 0 (poor QOL) to 100
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(maximum QOL); the valid Persian format of original questionnaire was used in this study
[19]. Additionally, total score of IBS was measured by a VAS of 100 mm scale to assess the total
impact of IBS symptoms on the quality of life at week 0, 6 and 10 (follow-up period) [21].
Weekly follow-up was done by phone call and the probable adverse effects of supplements
were asked at each call. Tablet counts were used to assess adherence to treatment and compli-
ance of study participants. The total score of IBS was assessed at week 10 to evaluate the effect
of intervention after cessation of supplementation.
The primary outcome measure was score of IBS-SSS questionnaire and the secondary out-
come measures were IBS- QOL score and total score.
Based on the result of the study by Ligaarden et al.[22], we used G-Power software to calcu-
late sample size for this study. Considering independent t-test for comparison of means of IBS
Score between vitamin D group versus placebo and Soy flavonoid group versus placebo and
targeting the significance level of the test at 0.05, twenty one subjects in each group would be
enough for detecting 1.6 difference in means of two groups with study power of 80% (S1 = 1.88
and S2 = 1.77). This sample size would be sufficient to detect an interaction effect as large as
twice of main effects. Considering 15% loss to follow up, we allocated 25 patients for each
group.
Statistical analysis
Quantitative data were presented as mean (SD) and qualitative data were reported as frequency
and percentage. Analysis of variance (ANOVA), chi-square test and fisher’s exact test, were
used to compare baseline factors between groups. General linear models (Two-way ANOVA)
were used to analyze the main effects and interaction effect of two interventions. The model-
based adjusted means (SE) were reported for this type of analysis. Data were analyzed using
SPSS software version 20 (Released 2011. IBM SPSS Statistics for Windows, Version 20.0.
Armonk, NY: IBM Corp.). P-values< 0.05 were considered statistically significant. Data ana-
lyzed by intention-to-treat (ITT) approach. Overall 10% of data were missing. We used regres-
sion models for imputing missing values. For reporting results of analysis, we used a table
format which introduced by Wang et al [23] for factorial designs.
Results
One hundred women with IBS participated in this clinical trial and were assigned to four
groups randomly: P+ P group (n = 25), S+P group (n = 25), D+ P group (n = 25) and S+ D
group (n = 25). All data on participants’ entrance and retention in the groups have been shown
in Fig 1. The baseline demographic data of four groups were not significantly different
(Table 1). There were no significant differences in dietary intakes among four groups (Results
were not shown).
Primary outcome
The interaction effect of soy isoflavones with vitamin D was not statistically significant for
IBS-SSS (p = 0.197); so, we could discuss about main effects. The main effects of soy isoflavones
and vitamin D on the IBS- SSS were statistically significant (p = 0.001, p = 0.047 respectively).
The IBS- SSS was significantly lower in patients who received soy isoflavones versus patients
who did not receive it (adjusted mean = 12.93 versus adjusted mean = 17.83). Adjusted mean
of IBS- SSS was lower in patients who received vitamin D in comparison to patients who did
not receive vitamin D (adjusted mean = 13.59 versus adjusted mean = 16.64) (Table 2). The
effects of soy isoflavones and/or vitamin D supplementation on the abdominal pain severity
(Fig 2), abdominal pain duration (Fig 3), abdominal distension (Fig 4), satisfaction of bowel
Soy and Vitamin D in Irritable Bowel Syndrome
PLOSONE | DOI:10.1371/journal.pone.0158545 August 4, 2016 4 / 11
habits (Fig 5), life disruption (Fig 6) after 6 weeks was significantly different among the study
groups.
Secondary outcomes
The IBS- QOL questionnaires were filled in by all participants at week 0 and week 6. The inter-
action effect of vitamin D and soy isoflavones on the QOL scores was not statistically signifi-
cant (p = 0.675); so, we could interpret the main effects of soy isoflavones and vitamin D.Soy
Fig 1. Flow Diagram of the study.
doi:10.1371/journal.pone.0158545.g001
Table 1. Characteristics of participants in different groups at the baseline.
Soy + P (n = 25) Soy + D (n = 25) P + P (n = 25) D + P (n = 25) P-value
Age (yr) mean(SD) 42.96 (11.70) 40.16 (13.46) 39.76 (12.99) 41.32 (12.62) 0.8121
Weight (kg) mean(SD) 71.94 (10.67) 65.60 (14.86) 65.90 (11.95) 66.40 (10.10) 0.2041
Height (cm) mean(SD) 160.40 (5.24) 157.54 (5.62) 161.08 (6.09) 159.71 (5.60) 0.1301
Waist circumference (cm) mean(SD) 90.50 (9.81) 87.06 (13.95) 87.66 (11.06) 89.00 (11.32) 0.5441
BMI (kg/m2) mean(SD) 28.08 (4.82) 26.49 (5.87) 25.35 (3.93) 26.04 (4.15) 0.2251
Serum vitamin D (ng/ml) mean(SD) 20.87 (8.34) 20.92 (8.32) 21.23 (8.45) 21.10 (8.23) 0.9811
Subtypes N (%)
IBS-C 19 (59.4) 12 (46.2) 22 (62.9) 21 (65.6) 0.3743
IBS-D 5 (15.6) 3 (11.5) 4 (11.4) 3 (9.4)
IBS-M 4 (12.5) 8 (30.8) 7 (20) 5 (15.6)
IBS-U 4 (12.5) 3 (11.5) 2 (5.7) 2 (6.3)
IBS-SSS mean (SD) 240.00 (7.1) 240.64 (110.56) 250.56 (120.36) 250.56 (90.60) 0.9641
IBS-QOL mean (SD) 64.48 (27.85) 58.48 (31.04) 46.32 (30.06) 58.40 (31.41) 0.1951
Total score mean (SD) 21.60 (15.92) 23.80 (13.48) 22.40 (15.55) 20.40 (15.13) 0.8791
Smoking N (%) 2 (8.00) 3(12.00) 2 (8.00) 0 (0.00) 0.5082
Menopause N (%) 10(40.00) 8 (32.00) 8(32.00) 8(32.00) 0.9113
1- Statistical signiﬁcance test was done by ANOVA.
2- Statistical signiﬁcance test was done by Fisher’s exact test.
3- Statistical signiﬁcance test was done by Pearson chi-square.
SD: Standard deviation; Yr: year; Kg: kilogram; M: meter; cm: centimeter; IBS-C: Constipation; IBS-D: Diarrhea; IBS-M: Mixed; IBS-U: Unsubtyped.
doi:10.1371/journal.pone.0158545.t001
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isoflavones improved the total score of QOL significantly (adjusted mean for patients who
were received soy isoflavones was 34.55 while adjusted mean for patients who were not
received it was 44.96, p- value = 0.004). Also, the vitamin D supplementation significantly
improved the IBS- QOL scores (The adjusted mean of IBS- QOL score was 35.48 for patients
who were received vitamin D, while the adjusted mean for patients who were not received it
was 44.04, p- value = 0.015) (Table 3).
The interaction effect of soy isoflavones and vitamin D on the total score of IBS was signifi-
cant (p<0.001) (Table 4); so, the overall effects of soy isoflavones and vitamin D on the total
score could not be interpreted. However, we assessed the effect of vitamin D on total score in
placebo and soy isoflavones groups separately. The effect of vitamin D on the total score was
statistically significant in placebo group (the adjusted mean of total score was 68.60 for patients
who were received vitamin D while the adjusted mean for placebo group was 29.28, p-
value< 0.001).There was not any statistically significant difference between vitamin D and pla-
cebo groups in patients who received soy isoflavones in the case of total score (Table 5).
Discussion
To our knowledge, this study is the first 2× 2 factorial randomized clinical trial that evaluated
the effects of soy isoflavones and vitamin D supplementation on clinical manifestations, quality
of life and total score in women with IBS. Our findings have revealed that co-administration of
soy isoflavones with vitamin D could not improve the IBS- SSS, and IBS- QOL scores, although
each treatment reduced significantly the symptoms severity and quality of life. The interaction
Table 2. The effects of soy isoflavones and/or vitamin D supplementation on the IBS- SSS after 6 weeks.
Vitamin D adjusted mean 1(SE) Total
No Yes
Soy isoﬂavones adjusted mean1 (SE) No 200.36(10.54) 150.31(10.51) 170.83(10.08)
Yes 120.91(10.53) 110.86(10.51) 120.93(10.08)
Total 160.64(10.09) 130.59(10.09)
Soy isoﬂavones main effect F = 8.15 (df = 1), P-value = 0.001**
Vitamin D main effect F = 0.89 (df = 1), P-value = 0.047*
Interaction effect F = 3.79 (df = 1), P-value = 0.195
1- Adjusted for IBS- QOL and IBS- SSS baseline values,
2- * p-value<0.05;
3- ** p-value<0.001
doi:10.1371/journal.pone.0158545.t002
Fig 2. The effects of soy isoflavones and/or vitamin D supplementation on abdominal pain severity
after 6 weeks; results are adjusted for the baseline values and IBS subtype. S+P: soy isoflavones and
placebo of vitamin D group, S+D: soy isoflavones and vitamin D group, P+P: placebo of soy isoflavones and
placebo of vitamin D group, D+P: vitamin D and placebo of soy isoflavones group.* pso of v.
doi:10.1371/journal.pone.0158545.g002
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effect of soy isoflavones and vitamin D on IBS total score was significant, which indicates the
synergistic effect of these bioactive metabolites on the total score of IBS.
The total score of IBS was reduced as the interaction effect of soy isoflavones with vitamin
D; so, the synergistic effect of these treatments could be possible. The results of follow up total
score at week 10 was similar, which indicates that even after cessation of supplements, the
Fig 3. The effects of soy isoflavones and/or vitamin D supplementation on abdominal pain duration
after 6 weeks; results are adjusted for the baseline values and IBS subtype. S+P: soy isoflavones and
placebo of vitamin D group, S+D: soy isoflavones and vitamin D group, P+P: placebo of soy isoflavones and
placebo of vitamin D group, D+P: vitamin D and placebo of soy isoflavones group.* pso of v.
doi:10.1371/journal.pone.0158545.g003
Fig 4. The effects of soy isoflavones and/or vitamin D supplementation on abdominal distension after
6 weeks; results are adjusted for the baseline values and IBS subtype. S+P: soy isoflavones and
placebo of vitamin D group, S+D: soy isoflavones and vitamin D group, P+P: placebo of soy isoflavones and
placebo of vitamin D group, D+P: vitamin D and placebo of soy isoflavones group.* pso of v.
doi:10.1371/journal.pone.0158545.g004
Fig 5. The effects of soy isoflavones and/or vitamin D supplementation on satisfaction of bowel
habits after 6 weeks; results are adjusted for the baseline values and IBS subtype. S+P: soy
isoflavones and placebo of vitamin D group, S+D: soy isoflavones and vitamin D group, P+P: placebo of soy
isoflavones and placebo of vitamin D group, D+P: vitamin D and placebo of soy isoflavones group.* pso of v.
doi:10.1371/journal.pone.0158545.g005
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beneficial effects of bioactive compounds in suppression of abdominal pain and flatulence was
observed. There is no clinical trial evaluating the effects of soy products or vitamin D on clini-
cal manifestation of IBS. The active form of vitamin D can modulate ERs and activate the
nuclear signaling of them in the colonic smooth muscles[24]. In vitro studies have shown that
both soy phytoestrogens and vitamin D can strengthen each other to bind ERs in smooth mus-
cle cells and modulate the expression of ER proteins[24]. Besides the impact of these nutrients
on the specific receptors in colonic tissue, they may affect the psychological items of IBS and
soothe the chronic visceral pain [25]. Moreover, vitamin D is an essential nutrient in optimal
homeostasis of intestinal mucosal barrier and vitamin D deficiency is related to more severe
clinical features of IBS [26].
This study has some limitations: the study was done according to our planned protocol with
a good power in sample size estimation; however, the results suggest that we might reach to a
better results if the sample size was higher.Another limitation of this study was that judgment
of QOL outcomes in randomized clinical trials is sophisticated because there are different spe-
cific domains for each QOL item and they are associated with severity of disease, emotional
stress, mood and comorbidities [27], however, even small differences in QOL scores can indi-
cate a critical clinical variations [28]. Furthermore, randomization in equal block size of four,
although helps to ensure equal group size, may hinder the effectiveness of allocation
concealment.
This study has several strengths; one of the strengths of this study is its factorial design,
which is an efficient analytical method of concurrently evaluating two independent treatments
Fig 6. The effects of soy isoflavones and/or vitamin D supplementation on life disruption after 6
weeks; results are adjusted for the baseline values and IBS subtype. S+P: soy isoflavones and placebo
of vitamin D group, S+D: soy isoflavones and vitamin D group, P+P: placebo of soy isoflavones and placebo
of vitamin D group, D+P: vitamin D and placebo of soy isoflavones group.* pso of v
doi:10.1371/journal.pone.0158545.g006
Table 3. The effects of soy isoflavones or/ and vitamin D on IBS- QOL after 6 weeks.
Vitamin D adjusted mean1(SE) Total
No Yes
Soy isoﬂavones adjusted mean1 (SE) No 49.98 (3.51) 39.95 (3.45) 44.96 (2.46)
Yes 38.09 (3.48) 31.01(3.45) 34.55 (2.46)
Total 44.04 (2.44) 35.48 (2.44)
Soy isoﬂavones main effect F = 8.88 (df = 1), P-value = 0.004*
Vitamin D main effect F = 6.12 (df = 1), P-value = 0.015*
Interaction effect F = 0.177 (df = 1), P-value = 0.675
1- Adjusted for IBS- QOL baseline value,
* p-value<0.05
doi:10.1371/journal.pone.0158545.t003
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and finally, application of a disease- specific SSS and QOL questionnaires that demonstrate
robust and reliable data on the severity scores and psychometric properties is strength of this
study. We conducted a prior study to investigate the effects of soy isoflavones on these clinical
outcomes[29]. In this study, we added vitamin D to evaluate their co-administration effect.
In conclusion, the total score of IBS improved significantly through the interaction effect of
soy isoflavones and vitamin D that can suggest the synergistic effect of these nutrients on intes-
tinal hypersensitivity. Our findings did not support the synergistic effects of co-administration
of soy isoflavones and vitamin D on the IBS- SSS and IBS- QOL, although the soy isoflavones
or vitamin D alone reduced the IBS-SSS and IBS- QOL significantly. Our findings provide
some clinical evidence for effects of soy isoflavones and vitamin D on IBS symptoms and qual-
ity of life. Further clinical trialswith longer follow up and higher sample size are needed to
determine the possible effects of co-administration of these supplements on clinical outcomes
and management of IBS symptoms clearly.
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Table 4. The effects of soy isoflavones or/ and vitamin D on the total score of IBS after 6 weeks.
Vitamin D adjusted mean1(SE) Total
No Yes
Soy isoﬂavones adjusted mean1 (SE) No 29.27(4.42) 69.37(4.35) 49.32(3.10)
Yes 70.63(4.38) 72.02(4.35) 71.32(3.10)
Total 49.95(3.07) 70.69(3.07)
Soy isoﬂavones main effect F = 24.85 (df = 1), P-value = <0.001**
Vitamin D main effect F = 22.76 (df = 1), P-value = <0.001**
Interaction effect F = 19.41 (df = 1), P-value = <0.001**
1- Adjusted for IBS- QOL and total score baseline values
** P-value<0.001
doi:10.1371/journal.pone.0158545.t004
Table 5. Estimation of effect of vitamin D on total score in Placebo and Soy isoflavones groups separately.
Placebo Adjusted mean1(SE) Vitamin D Adjusted mean1(SE) p-value
Placebo (n = 50) 29.28 (4.46) 68.60 (4.46) <0.001**
Soy isoﬂavones (n = 50) 71.24 (4.34) 72.17 (4.34) 0.882
1- Adjusted for IBS- QOL and total score baseline values
** P-value<0.001
doi:10.1371/journal.pone.0158545.t005
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